Cargando…

Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation

BACKGROUND: Polybactum (Effik International, Brussels, Belgium) is a vaginal mucoadhesive product (medical device) designed to form a film that acts as a mechanical barrier with the aim of inhibiting colonization by specific pathogens. It contains polycarbophil, a bioadhesive agent, and lauryl gluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardolino, Luca Ivan, Meloni, Marisa, Brugali, Giuseppe, Corsini, Emanuela, Galli, Corrado Lodovico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067097/
https://www.ncbi.nlm.nih.gov/pubmed/27766122
http://dx.doi.org/10.1016/j.curtheres.2016.07.002
_version_ 1782460590742044672
author Ardolino, Luca Ivan
Meloni, Marisa
Brugali, Giuseppe
Corsini, Emanuela
Galli, Corrado Lodovico
author_facet Ardolino, Luca Ivan
Meloni, Marisa
Brugali, Giuseppe
Corsini, Emanuela
Galli, Corrado Lodovico
author_sort Ardolino, Luca Ivan
collection PubMed
description BACKGROUND: Polybactum (Effik International, Brussels, Belgium) is a vaginal mucoadhesive product (medical device) designed to form a film that acts as a mechanical barrier with the aim of inhibiting colonization by specific pathogens. It contains polycarbophil, a bioadhesive agent, and lauryl glucoside (LG), a nonionic surfactant that reinforces the barrier effect through its tensioactive properties. OBJECTIVE: To assess the local safety profile, tolerability, and efficacy of Polybactum formulations. METHODS: The following studies were performed on 3 Polybactum formulations: 2 ovules (Type 1: LG 0.04% and Type 2: LG 0.1%) and 1 gel formulation. Bacteriologic tests assessing the effects on normal vaginal flora and pathogens; in vitro and in vivo tests designed to assess cytotoxicity, as well as irritant and sensitizing potentials; biocompatibility, barrier, residence time, and absorption tests using reconstituted human vaginal epithelium were performed. RESULTS: Polybactum is a selective bacteriostatic agent that is active against Streptococcus agalactiae and Gardnerella vaginalis while sparing normal vaginal flora; that is, Lactobacillus spp. It had no cytotoxic, irritant, and sensitizing effects nor did it impair barrier and fence functions of the vaginal epithelium. The Type 1 ovule showed film-forming properties in vitro. Finally, LG absorption through reconstituted human vaginal epithelium was negligible, ruling out the risk for possible systemic toxicity. CONCLUSIONS: This favorable preclinical profile is encouraging and supports clinical studies on Polybactum Type 1 ovules for the prevention and management of recurring bacterial vaginosis.
format Online
Article
Text
id pubmed-5067097
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-50670972016-10-20 Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation Ardolino, Luca Ivan Meloni, Marisa Brugali, Giuseppe Corsini, Emanuela Galli, Corrado Lodovico Curr Ther Res Clin Exp Original Research BACKGROUND: Polybactum (Effik International, Brussels, Belgium) is a vaginal mucoadhesive product (medical device) designed to form a film that acts as a mechanical barrier with the aim of inhibiting colonization by specific pathogens. It contains polycarbophil, a bioadhesive agent, and lauryl glucoside (LG), a nonionic surfactant that reinforces the barrier effect through its tensioactive properties. OBJECTIVE: To assess the local safety profile, tolerability, and efficacy of Polybactum formulations. METHODS: The following studies were performed on 3 Polybactum formulations: 2 ovules (Type 1: LG 0.04% and Type 2: LG 0.1%) and 1 gel formulation. Bacteriologic tests assessing the effects on normal vaginal flora and pathogens; in vitro and in vivo tests designed to assess cytotoxicity, as well as irritant and sensitizing potentials; biocompatibility, barrier, residence time, and absorption tests using reconstituted human vaginal epithelium were performed. RESULTS: Polybactum is a selective bacteriostatic agent that is active against Streptococcus agalactiae and Gardnerella vaginalis while sparing normal vaginal flora; that is, Lactobacillus spp. It had no cytotoxic, irritant, and sensitizing effects nor did it impair barrier and fence functions of the vaginal epithelium. The Type 1 ovule showed film-forming properties in vitro. Finally, LG absorption through reconstituted human vaginal epithelium was negligible, ruling out the risk for possible systemic toxicity. CONCLUSIONS: This favorable preclinical profile is encouraging and supports clinical studies on Polybactum Type 1 ovules for the prevention and management of recurring bacterial vaginosis. Elsevier 2016-07-25 /pmc/articles/PMC5067097/ /pubmed/27766122 http://dx.doi.org/10.1016/j.curtheres.2016.07.002 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Ardolino, Luca Ivan
Meloni, Marisa
Brugali, Giuseppe
Corsini, Emanuela
Galli, Corrado Lodovico
Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation
title Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation
title_full Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation
title_fullStr Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation
title_full_unstemmed Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation
title_short Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation
title_sort preclinical evaluation of tolerability of a selective, bacteriostatic, locally active vaginal formulation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067097/
https://www.ncbi.nlm.nih.gov/pubmed/27766122
http://dx.doi.org/10.1016/j.curtheres.2016.07.002
work_keys_str_mv AT ardolinolucaivan preclinicalevaluationoftolerabilityofaselectivebacteriostaticlocallyactivevaginalformulation
AT melonimarisa preclinicalevaluationoftolerabilityofaselectivebacteriostaticlocallyactivevaginalformulation
AT brugaligiuseppe preclinicalevaluationoftolerabilityofaselectivebacteriostaticlocallyactivevaginalformulation
AT corsiniemanuela preclinicalevaluationoftolerabilityofaselectivebacteriostaticlocallyactivevaginalformulation
AT gallicorradolodovico preclinicalevaluationoftolerabilityofaselectivebacteriostaticlocallyactivevaginalformulation